AmerisourceBergen Declares Quarterly Dividend
The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC) today declared a quarterly dividend of
$0.365 per common share, payable June 5, 2017, to stockholders of record at the close of business on May 22, 2017.
About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both
healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With
services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services,
AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health.
With over $145 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 19,000
people. AmerisourceBergen is ranked #12 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook,"
"forecast," "would," "could," "should," "can," "will," "project," "intend," "plan," "continue," "sustain," "synergy," "on track,"
"believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are
intended to identify such forward-looking statements. These statements are based on management's current expectations and are
subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on
assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors
that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable
trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and
industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and
services; changes in pharmaceutical market growth rates; substantial defaults in payment, material reduction in purchases by or the
loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier mix; the retention of key customer or
supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or
suppliers; changes to customer or supplier payment terms; the disruption of AmerisourceBergen's cash flow and ability to
return value to its stockholders in accordance with its past practices; risks associated with the strategic, long-term relationship
between Walgreens Boots Alliance, Inc. and AmerisourceBergen, including with respect to the pharmaceutical
distribution agreement and/or the global sourcing arrangement; changes in the United States healthcare and regulatory
environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid;
increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; federal and state
government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled
substances; federal and state prosecution of alleged violations of related laws and regulations, and any related litigation,
including shareholder derivative lawsuits or other disputes relating to our distribution of controlled substances; increased
federal scrutiny and qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and
regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services and any related
litigation; material adverse resolution of pending legal proceedings; declining reimbursement rates for pharmaceuticals; the
acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration
of PharMEDium, or the inability to capture all of the anticipated synergies related thereto; regulatory action in connection with
the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business; declining
economic conditions in the United States and abroad; financial market volatility and disruption; the loss, bankruptcy or
insolvency of a major supplier; interest rate and foreign currency exchange rate fluctuations; managing foreign expansion,
including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and
regulations; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated
with data privacy regulation and the international transfer of personal data; changes in tax laws or legislative initiatives that
could adversely affect AmerisourceBergen's tax positions and/or AmerisourceBergen’s tax liabilities or adverse resolution
of challenges to AmerisourceBergen's tax positions; natural disasters or other unexpected events that
affect AmerisourceBergen's operations; the impairment of goodwill or other intangible assets, resulting in a charge to
earnings; and other economic, business, competitive, legal, tax, regulatory and/or operational factors
affecting AmerisourceBergen's business generally. Certain additional factors that management believes could cause actual
outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk
Factors) in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016 and elsewhere in that
report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.
AmerisourceBergen Corporation
Keri P. Mattox
Vice President, Corporate & Investor Relations
610-576-7801
kmattox@amerisourcebergen.com
or
Bennett S. Murphy
Director, Corporate & Investor Relations
610-727-3693
bmurphy@amerisourcebergen.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170509005229/en/